<document xmlns="http://cnx.rice.edu/cnxml">
  <title>Calcium Channel Blockers</title>
  <metadata xmlns:md="http://cnx.rice.edu/mdml">
    <md:title>Calcium Channel Blockers</md:title>
    <md:content-id>m00006</md:content-id>
    <md:abstract><para id="para-00001">By the end of this section, you will be able to:</para>
  <list id="list-00001">
    <item>LO18.5.1 Discuss the use of calcium channel blocker drugs used to treat hypertension and angina.</item>
    <item>LO18.5.2 Differentiate between calcium channel blocker drugs used in the treatment of  hypertension and angina.</item>
    <item>LO18.5.3 Describe nursing implications related to calcium channel blocker drugs used to treat hypertension and angina.</item>
    <item>LO18.5.4 Develop an education plan related to calcium channel blocker drugs used in the treatment of hypertension and angina.</item>
  </list>
  </md:abstract>
    <md:uuid>dc3f05e4-650a-459f-8f33-a96a99c24a28</md:uuid>
  </metadata>
  <content>
    <section id="sect-00001">
      <title>Introduction and Use</title>
    <para id="para-00002"><term id="term-00001">Calcium channel blockers</term> are a classification of drugs that block calcium from entering cells by binding to long-acting voltage-gated calcium channels in the heart, smooth muscle, and pancreas. Calcium causes vasoconstriction. Calcium channel blockers inhibit calcium and allow for vasodilation, thereby causing the heart rate to slow and blood pressure to lower. Calcium channel blockers are commonly used to treat hypertension, angina, and arrhythmias.</para>

    <para id="para-00004">Calcium channel blockers are classified as nondihydro-pyridines or dihydro-pyridines. Dihydro-pyridines are peripheral vasodilators and lower blood pressure and heart rate; they are used to treat post-intracranial hemorrhage, vasospasm, and migraines. In addition to their action on the peripheral vasculature, nondihydro-pyridines inhibit sinoatrial (SA) and atrioventricular (AV) nodes, slowing cardiac conduction, slowing the heart rate, and decreasing oxygen demand.</para>

    <para id="para-00005">Calcium channel blockers may be used alone or in combination with other drugs. They are highly protein bound, which increases the volume of distribution within the body. Calcium channel blockers are available in long- and short-acting formulas.</para>

    <note class="special-considerations" id="note-00002">
      <title>Calcium Channel Blockers</title>
      <para id="para-00006">Calcium channel blockers are among the most effective antihypertensive classification of drug for use in African Americans, clients of African descent, and older clients.
      </para>
      <para id="para-00007">Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681568/#:~:text=Calcium%20blockers%20are%20with%20diuretics,%2F%3D%20110%20mm%20Hg</para>
    </note>

    <note class="safety-alert" id="note-00003">
      <title>Calcium Channel Blockers</title>
      <para id="para-00008">Abrupt discontinuation of calcium channel blockers may cause chest pain.</para>
    </note>

    <para id="para-00009"><link target-id="table_18_05_001"/>lists common calcium channel blockers and typical routes and dosing for adult and pediatric clients.<newline/><link target-id="table_18_05_002"/>is a drug prototype chart for calcium channel blockers featuring amlodipine. It lists drug class, mechanism of action, dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>

    <table id="table_18_05_001" class="drugs" summary="Alt text here.">
      <tgroup cols="3">
        <thead class="blue-text">
          <row>
            <entry>Drug</entry>
            <entry>Routes and Dosage Ranges: Adults</entry>
            <entry>Routes and Dosage Ranges: Children</entry>
          </row>
        </thead>
        <tbody>
          <row>
            <entry><emphasis effect="italics">Atenolol</emphasis><newline/>
              (Tenormin)</entry>
            <entry>50–100 mg daily orally in 1–2 divided doses</entry>
            <entry>0.1–1 mg/kg daily orally in 1–2 divided doses, maximum dose 2 mg/kg up to 100 mg daily in 1–2 divided doses</entry>
          </row>
          <row>
            <entry><emphasis effect="italics">Carvediolol</emphasis><newline/>
              (Coreq)
              </entry>
            <entry>6.25–25 mg daily orally, maximum dose 25 mg daily</entry>
            <entry>This drug is not recommended for use in children.</entry>
          </row>
          <row>
            <entry><emphasis effect="italics">Labetalol</emphasis><newline/>(Trandate)</entry>
            <entry>100–400 mg twice daily orally, maximum dose 2400 mg daily for severe hypertension</entry>
            <entry>1–3 mg/kg orally daily, maximum dose 10–12 mg/kg or 1200 mg daily</entry>
          </row>
          <row>
            <entry><emphasis effect="italics">Metoprolol</emphasis><newline/>(Lopressor)</entry>
            <entry>50–400 mg daily orally, maximum dose 400 mg daily</entry>
            <entry>
              Immediate release 1–2 mg/kg orally daily in 2 doses, maximum dose 6 mg/kg maximum dose 200 mg daily<newline count="2"/>
              Sustained release 1 mg/kg daily orally, maximum dose 200 mg daily
            </entry>
          </row>
          <row>
            <entry><emphasis effect="italics">Nadolol</emphasis><newline/>(Corgard)</entry>
            <entry>40–320 mg daily orally</entry>
            <entry>6–16 years old: 1.3 mg/kg daily orally, maximum dose 2.7 mg/kg up to 160 mg daily</entry>
          </row>
          <row>
            <entry><emphasis effect="italics">Propranolol</emphasis><newline/>(Inderal LA)</entry>
            <entry>40 mg twice daily orally, maximum dose 640 mg daily</entry>
            <entry>1 mg/kg daily orally, maximum dose 10 mg/kg daily</entry>
          </row>
        </tbody>
      </tgroup>
      <caption>Drug Emphasis Table: Beta Blockers</caption>
    </table>

    <table id="table_18_05_002" summary="Alt text here.">
      <tgroup cols="2">
        <tbody>
        <row>
          <entry>
            <emphasis effect="bold"><span class="blue-text">Drug Class</span></emphasis><newline/>
            Beta-adrenergic blocker<newline/>
            <emphasis effect="bold"><span class="blue-text">Mechanism of Action</span></emphasis><newline/>
            <emphasis effect="italics">Metoprolol tartrate blocks beta 1 receptors, thereby decreasing cardiac workload by slowing the heart and decreasing the systolic blood pressure.</emphasis>
          </entry>
          <entry>
            <emphasis effect="bold"><span class="blue-text">Drug Dosage</span></emphasis><newline/>
            <emphasis effect="bold"><span class="blue-text">Adult:</span></emphasis> 50–400 mg orally twice daily<newline/>
            <emphasis effect="bold"><span class="blue-text">Pediatric:</span></emphasis> immediate release 1–2 mg/kg orally daily in 2 doses, maximum dose 6 mg/kg, 200 mg daily<newline/>
            <emphasis effect="bold"><span class="blue-text">Pediatric:</span></emphasis> sustained release 1 mg/kg daily orally, maximum dose 200 mg daily
          </entry>
        </row>
        <row>
          <entry>
            <emphasis effect="bold"><span class="blue-text">Indications</span></emphasis><newline/>
            To control hypertension<newline/>
            In the treatment of angina, acute myocardial infarction, and heart failure<newline count="2"/>
    
            <emphasis effect="bold"><span class="blue-text">Therapeutic Effects</span></emphasis><newline/>
            Lowers blood pressure<newline/>
            Decreases cardiac workload
          </entry>
          <entry>
            <emphasis effect="bold"><span class="blue-text">Drug Interactions</span></emphasis><newline/>
            <emphasis effect="italics">Albuterol</emphasis> (Ventolin)<newline/>
            <emphasis effect="italics">Clonidine</emphasis> (Catapres)<newline/>
            <emphasis effect="italics">Mefloquine</emphasis> (Lariam)<newline/>
    
            <emphasis effect="bold"><span class="blue-text">Food Interactions</span></emphasis><newline/>
            Caffeine<newline/>
            Alcohol<newline/>
            Tobacco
          </entry>
        </row>
        <row>
          <entry>
            <emphasis effect="bold"><span class="blue-text">Adverse Effects</span></emphasis>
            <list list-type="bulleted" bullet-style="none" id="list-00002">
              <item>Fatigue/weakness</item>
              <item>Dizziness</item>
              <item>Headache</item>
              <item>Blurred vision</item>
              <item>Dry mouth</item>
              <item>Nausea/vomitting/diarrhea</item>
              <item>Drowsiness/insomnia</item>
              <item>Tinnitus</item>
              <item>Peripheral edema</item>
              <item>Erectile dysfunction</item>
            </list>
          </entry>
          <entry>
            <emphasis effect="bold"><span class="blue-text">Contraindications</span></emphasis><newline/>
            Hypersensitivity, AV block, cardiogenic shock, hypotension, acute heart failure, bradycardia<newline count="2"/>
            Caution: thyroid impairment, hepatic impairment, asthma, peripheral vascular disease, diabetes mellitus, COPD, cerebrovascular disease
          </entry>
        </row>
      </tbody>
      </tgroup>
      <caption>Drug Prototype Table: Metoprolol Tartrate</caption>
    </table>





    <section id="sect-00002">
      <title>Adverse Effects</title>
      <para id="para-00010">Adverse effects include dizziness, constipation, palpitations, fatigue, flushing, nausea, rash, headache, and swelling in the legs and feet. Serious side effects include thrombocytopenia, hypotension, and hyperglycemia.</para>
    </section>

    <section id="sect-00003">
      <title>Contraindications</title>
      <para id="para-00011">Clients with a hypersensitivity to calcium channel blockers or their components should not use this classification of drug. Other contraindications include sick sinus syndrome, having a pacemaker, severe hypotension, a history of myocardial infarction, or a history of pulmonary congestion.</para>
    </section>

    <section id="sect-00004">
      <title>Nursing Implications</title>
      <para id="para-00012">The nurse should monitor the client for interactions because many medications and herbal supplements, such as St. John’s wort, interact with calcium channel blockers. Grapefruit juice can affect the action of certain calcium channel blockers. The nurse should assess and monitor the client for adverse effects and contraindications. The nurse also should provide client teaching regarding the drug and when to call the health care provider. See below for additional client teaching guidelines.</para>
    </section>

<note class="client-teaching" id="note-00004">
  <title>Guidelines for Calcium Channel Blockers</title>
  <para id="para-00013">
    <emphasis effect="bold">The client should:</emphasis>
        <list list-type="bulleted" id="list-00003">
          <item>Report side effects such as sore or bleeding gums, severe headaches, dizziness, lightheadedness, flushing, nausea, and leg swelling to their health care provider.</item>
          <item>Take this medication with food to avoid GI upset, nausea, and vomiting.</item>
        </list>
        <emphasis effect="bold">The client <emphasis effect="italics">should not</emphasis>:</emphasis>
        <list list-type="bulleted" id="list-00004">
          <item>Take amlodipine with grapefruit juice because this may cause increased blood levels of amlodipine, which can increase the therapeutic effect and risk for side effects.</item>
        </list>
  </para>
</note>

    <note class="unfolding-casestudy" id="note-00001">
      <title>Part B</title>
      <para id="para-00003">
        Read the following clinical scenario to answer the knowledge check questions that follow. This case study is a follow-up to <link document="m00002" target-id="note-00006">Case Study Part A</link>. Refer to the Answer Key at the end of the book for feedback.
      </para>
      <table class="unnumbered" summary="Insert Alt Text" id="table-00001">
        <tgroup cols="2">
          <colspec colnum="1" colname="c1"/>
          <colspec colnum="2" colname="c2"/>
          <tbody>
        <row>
          <entry namest="c1" nameend="c2"><para id="para-00034">Ms. Tran completes her diagnostic evaluation, and the health care provider diagnoses her with Hypertension Stage 2. She follows up with her health care provider one week later to get the results of her diagnostic studies and review her treatment plan.</para></entry>
        </row>
        <row>
          <entry namest="c1" nameend="c2">
            <exercise id="exer-00001">
              <problem id="prob-00001">
                <para id="para-00035"><link class="os-embed" url="#exercise/pharm_18_5_01"/></para>
              </problem>
             </exercise>
             <exercise id="exer-00002">
              <problem id="prob-00002">
                <para id="para-00036"><link class="os-embed" url="#exercise/pharm_18_5_02"/></para>
              </problem>
             </exercise>
          </entry>
        </row>
      </tbody>
      </tgroup>
      </table>
    </note>
  </section>
  </content>

  <glossary>
    <definition id="def-00001">
      <term>calcium channel blockers</term>
      <meaning>a classification of drugs that block calcium from entering cells by binding to long-acting voltage-gated calcium channels in the heart, smooth muscle, and pancreas</meaning>
    </definition>
  </glossary>
</document>